Avila appoints Andrew Hirsch CFO
This article was originally published in Scrip
Avila Therapeutics, a biotechnology company developing targeted covalent drugs, has made Andrew Hirsch its first chief financial officer. Mr Hirsch joins Avila from Biogen Idec where he served for 10 years, most recently as vice-president of corporate strategy and M&A.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.